Clinical Trial Search

Primary: Percentage of Participants With Cryptosporidium Infection From 72 Hours to 10 Days Post ABO809 Oral Administration — 50; 57.1; 60.0 percentage of participants

Primary: Longitudinal Diarrhea Prevalence — 7.6; 8.9 Incidence rate per 100 person-weeks

Primary: Incidence of Adverse Events — 1; 1; 0; 1 events

Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants

Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). — 189; 20 Participants

Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941

Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88

Primary: Primary Efficacy Outcome is Count of Participants With Two or Less Watery Bowel Movements Per Week During at Least Two Weeks of the Treatment Phase of the Optimal Dose…

Primary: Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1) — 21.30 hours

Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours

Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254

Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days

Primary: Nitazoxanide — 27 participants

Primary: Safety as Assessed by Number of Participants With Any Adverse Events (AE)s — 4; 4 Participants — p=0.8958

Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003

Primary: Reduction in Frequency of Defecation to 3 Times Per Day — 118; 24 Participants

Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants

Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer

Primary: Duration of Diarrhea — 2; 2 days — p=0.43

Primary: Number of Participants With Positive Rapid Enzyme Immunoassay (EIA) and Positive Antigen Detection EIA for Giardia and Resolution of Diarrhea (Less Than 3 Loose…

Primary: Analysis of Diarrheal Illness Etiologies Identified in Stool Culture Compared to the FilmArray™ Gastrointestinal (GI) Panel — 434; 19 Participants

Primary: Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT) — 10; 10; 13; 15 Participants — p=0.41

Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs

Primary: Campylobacteriosis — 13; 11 Participants

Primary: To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients. — 84; 85; 86 participants — p==0.02

Primary: Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment — 15; 48 Participants

Primary: Time to Initial Clinical Resolution of Norovirus Symptoms — 19; 11 days — p=0.459

Primary: Within and Between Group Comparisons of Disease Severity as Determined by Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS) — 282; 309; 221; 236 units on a scale

Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants